Brothers, C.H., Hernández, J.E., Cutrell, A.G., Curtis, L., Ait-Khaled, M., Bowlin, S.J., et al. (2009) Risk of myocardial infarction and abacavir therapy: No increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. Journal of Acquired Immune Deficiency Syndromes, 51, 20-28. doi:10.1097/QAI.0b013e31819ff0e6

has been cited by the following article:

• TITLE: Whole blood platelet aggregometry in HIV-infected patients on treatment with abacavir

  AUTHORS: Rosario Palacios Muñoz, Jose A. González-Correa, Josefa Ruiz, Enrique Nuño, Manuel Márquez, Jose P. de la Cruz, Jesús Santos

  KEYWORDS: Antiretroviral Therapy; Abacavir; Cardiovascular Risk; Platelet Activity

  JOURNAL NAME: Open Journal of Internal Medicine, Vol.2 No.2, June 11, 2012

  ABSTRACT: Purpose: To assess platelet activity in HIV-patients with and without antiretroviral therapy (ART), analysing the influence of the presence or absence of ABC in the regimen. Methods: Observational, pilot study, including 30 asymptomatic HIV-patients: 20 on ART for at least 24 weeks and with undetectable HIV viral load - 10 on ABC, 10 on tenofovir (TDF) - and 10 na?ve patients, and a control group of 10 HIV-negative subjects. No subject was receiving drugs with antiagregant activity. Platelet activity was assessed by measuring time-dependent platelet aggregometry (electrical impedance on fasting whole blood), induced by ADP (1.25, 2.5 μM), collagen (0.5, 1 μg/mL), arachidonic acid (100, 200 μM), and U46619 (receptor agonist of the tromboxano A2) (1.25, 2.5 μM). Statistic program: SPSS, 16.0. Results: Demographic, anthropometric data, and cardiovascular risk factors were similar in all groups, but older age and longer time of HIV infection in the ABC group (50.4 vs 36.1, 34.2 and 42.7 years, respectively; p